DK1509232T3 - Kombination af en NMDA-antagonist og acetylcholin-esterase inhibitorer til behandling af Alzheimers sygdom - Google Patents

Kombination af en NMDA-antagonist og acetylcholin-esterase inhibitorer til behandling af Alzheimers sygdom

Info

Publication number
DK1509232T3
DK1509232T3 DK03724895T DK03724895T DK1509232T3 DK 1509232 T3 DK1509232 T3 DK 1509232T3 DK 03724895 T DK03724895 T DK 03724895T DK 03724895 T DK03724895 T DK 03724895T DK 1509232 T3 DK1509232 T3 DK 1509232T3
Authority
DK
Denmark
Prior art keywords
disease
combination
acetylcholine esterase
nmda antagonist
treat alzheimer
Prior art date
Application number
DK03724895T
Other languages
Danish (da)
English (en)
Inventor
Lars Lykke Thomsen
Anders Gersel Pedersen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29713304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1509232(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Application granted granted Critical
Publication of DK1509232T3 publication Critical patent/DK1509232T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK03724895T 2002-05-31 2003-05-22 Kombination af en NMDA-antagonist og acetylcholin-esterase inhibitorer til behandling af Alzheimers sygdom DK1509232T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38446702P 2002-05-31 2002-05-31
DKPA200200844 2002-05-31
PCT/DK2003/000342 WO2003101458A1 (fr) 2002-05-31 2003-05-22 Combinaison d'un antagoniste de n-methyl d-aspartate et d'inhibiteurs de l'esterase d'acetylcholine pour le traitement de la maladie d'alzheimer

Publications (1)

Publication Number Publication Date
DK1509232T3 true DK1509232T3 (da) 2009-02-23

Family

ID=29713304

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03724895T DK1509232T3 (da) 2002-05-31 2003-05-22 Kombination af en NMDA-antagonist og acetylcholin-esterase inhibitorer til behandling af Alzheimers sygdom

Country Status (17)

Country Link
EP (1) EP1509232B1 (fr)
JP (1) JP2005528431A (fr)
AT (1) ATE414519T1 (fr)
AU (1) AU2003227516B2 (fr)
BR (1) BR0311375A (fr)
CY (1) CY1108725T1 (fr)
DE (1) DE60324788D1 (fr)
DK (1) DK1509232T3 (fr)
ES (1) ES2314200T3 (fr)
IL (1) IL165255A0 (fr)
MX (1) MXPA04011762A (fr)
NO (1) NO332754B1 (fr)
NZ (1) NZ536603A (fr)
PL (1) PL373903A1 (fr)
PT (1) PT1509232E (fr)
SI (1) SI1509232T1 (fr)
WO (1) WO2003101458A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2502432A1 (fr) * 2002-10-24 2004-05-06 Merz Pharma Gmbh & Co. Kgaa Therapie combinee faisant appel a des derives de 1-aminocyclohexane ainsi qu'a des inhibiteurs d'acetylcholinesterase
EP1703902B1 (fr) * 2004-01-05 2010-11-03 Merz Pharma GmbH & Co. KGaA Memantine destinee au traitement de la maladie d'alzheimer legere a moderee
EP1708707A1 (fr) * 2004-01-22 2006-10-11 Neurosearch A/S Composition pharmaceutique comprenant un inhibiteur du recaptage des neurotransmetteurs de monoamine et un antagoniste des recepteurs n-methyl-d-aspartate (nmda)
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
US20070213388A1 (en) * 2004-03-19 2007-09-13 Bruinsma Gosse B Acetylcholinesterase Inhibitors and N-Methyl-D-Aspartate Antagonists Useful in the Treatment of of Cognitive Disorders
RU2404750C2 (ru) * 2004-11-23 2010-11-27 Адамас Фармасьютикалс, Инк. Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP1874282B1 (fr) 2005-04-06 2010-09-15 Adamas Pharmaceuticals, Inc. Procedes et compositions pour le traitement des pathologies associees au systeme nerveux central
CA2604617C (fr) * 2005-04-28 2014-06-17 Eisai R&D Management Co., Ltd. Composition renfermant une drogue contre la demence
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
EP2089383B1 (fr) 2006-11-09 2015-09-16 Probiodrug AG Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
CA2679446C (fr) 2007-03-01 2016-05-17 Probiodrug Ag Nouvelle utilisation d'inhibiteurs de la glutaminyl cyclase
EP2142514B1 (fr) 2007-04-18 2014-12-24 Probiodrug AG Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase
CA2772488C (fr) 2009-09-11 2018-04-17 Probiodrug Ag Derives heterocycliques en tant qu'inhibiteurs de glutaminyle cyclase
CN102883601A (zh) 2009-12-02 2013-01-16 阿达玛斯医药公司 金刚烷胺组合物及其使用方法
EP2533645B1 (fr) 2010-02-09 2016-07-27 The Johns Hopkins University Procédés et compositions pour améliorer la fonction cognitive
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
EP2545047B9 (fr) 2010-03-10 2015-06-10 Probiodrug AG Inhibiteurs hétérocycliques de la glutaminyl cyclase (qc, ec 2.3.2.5)
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
ES2625135T3 (es) 2010-07-05 2017-07-18 Gambro Lundia Ab Un dispositivo de ultrafiltración ambulatoria, métodos relacionados y un producto de programa informático
TR201007110A2 (tr) 2010-08-25 2012-03-21 Bi̇lgi̇ç Mahmut Sinerjik etki gösteren kombinasyonlar
WO2012048871A1 (fr) 2010-10-12 2012-04-19 Merz Pharma Gmbh & Co. Kgaa Mémantine pour l'amélioration de la performance cognitive chez des sujets
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
FR2983732B1 (fr) * 2011-12-09 2013-11-22 Servier Lab Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}pharmaceutiques qui la contiennent
WO2013160728A1 (fr) * 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Composés à double ciblage pour le traitement de la maladie d'alzheimer
WO2014055047A1 (fr) * 2012-08-31 2014-04-10 Mahmut Bilgic Combinaison d'un agent actif dérivé de la quinone et d'une cholinestérase
WO2014035355A1 (fr) * 2012-08-31 2014-03-06 Mahmut Bilgic Combinaisons pharmaceutiques comprenant un agent actif dérivé de la quinone
WO2014078568A1 (fr) 2012-11-14 2014-05-22 The Johns Hopkins University Méthodes et compositions pour le traitement de la schizophrénie
GEP201706739B (en) * 2012-12-13 2017-09-25 H Lundbeck As Compositions comprising vortioxetine and donepezil
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
EP2968237A4 (fr) 2013-03-15 2016-08-31 Univ Johns Hopkins Procédés et compositions pour améliorer la fonction cognitive
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
US10925834B2 (en) 2015-05-22 2021-02-23 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
SG11201809726UA (en) * 2016-05-18 2018-12-28 Suven Life Sciences Ltd Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
KR101938872B1 (ko) * 2016-09-30 2019-01-16 주식회사 바이오파마티스 도네페질 또는 그의 약학적으로 허용 가능한 염 및 메만틴 또는 그의 약학적으로 허용 가능한 염을 함유하는 치매 및 인지기능 장애 예방 또는 치료용 약학 조성물 및 이의 제조방법
EP3532060A4 (fr) * 2016-10-28 2020-08-26 Chase Pharmaceuticals Corporation Combinaisons et utilisation de mémantine
TR201619184A2 (tr) 2016-12-22 2018-07-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Donepezi̇l ve memanti̇n i̇çeren kapsül bi̇leşi̇mleri̇
EP3461819B1 (fr) 2017-09-29 2020-05-27 Probiodrug AG Inhibiteurs de la glutaminyl-cyclase
EP4238555A3 (fr) 2019-05-31 2023-09-20 Tecnimede, Sociedade Técnico-Medicinal, SA Combinaison à dose fixe et à libération immédiate de mémantine et de donépézil

Also Published As

Publication number Publication date
PL373903A1 (en) 2005-09-19
CY1108725T1 (el) 2014-04-09
NO20045434L (no) 2004-12-13
NZ536603A (en) 2007-06-29
ES2314200T3 (es) 2009-03-16
PT1509232E (pt) 2009-01-07
NO332754B1 (no) 2013-01-07
MXPA04011762A (es) 2005-03-31
BR0311375A (pt) 2005-03-15
EP1509232A1 (fr) 2005-03-02
ATE414519T1 (de) 2008-12-15
DE60324788D1 (de) 2009-01-02
WO2003101458A1 (fr) 2003-12-11
IL165255A0 (en) 2005-12-18
EP1509232B1 (fr) 2008-11-19
AU2003227516A1 (en) 2003-12-19
JP2005528431A (ja) 2005-09-22
SI1509232T1 (sl) 2009-04-30
AU2003227516B2 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
DK1509232T3 (da) Kombination af en NMDA-antagonist og acetylcholin-esterase inhibitorer til behandling af Alzheimers sygdom
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
BR0308243A (pt) Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero
PL361404A1 (en) Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
DK1257550T3 (da) Blodplade-ADP-receptor-inhibitor
BRPI0407993B8 (pt) compostos inibidores de p38 e composições farmacêuticas compreendendo os mesmos
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
BRPI0417697A (pt) inibidores de protease de aspartila heterocìclicos
BRPI0617165A2 (pt) Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
CY1110385T1 (el) Χρηση αναστολεων της il-18 για τη θεραπεια και/ή προληψη της αθηροσκληρωσης
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
UY27362A1 (es) Métodos de usar inhibidores de epóxido hidrolasa soluble
DE60214198D1 (de) Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen
DE60312017D1 (de) Sulfonderivate zur hemmung von gamma-secretase
NO996578L (no) Urokinase-inhibitorer
ES2194202T3 (es) Compuestos polimorfos.
DK1456380T3 (da) SMAD7-inhibitorer til behandling af CNS-sygdomme
DE60323765D1 (de) Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
ATE452884T1 (de) Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase
HUP0401854A2 (hu) COX-2 inhibitorokat és aszpirint tartalmazó kombinációk
ATE234359T1 (de) Fusionsproteine bestehend aus gewebefaktor- kunitzdomäne als inhibitoren des faktors viia
ATE443044T1 (de) Tace inhibitoren
DK1007040T3 (da) Anvendelsen af phanquinon til behandlingen af Alzheimers sygdom
DE60134735D1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
EA200601592A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора